Global Medical & Evidence Strategy Lead: Bemdaneprocel, Parkinson's Disease

Global Medical & Evidence Strategy Lead:
Bemdaneprocel, Parkinson's Disease

At Bayer we’re visionaries, driven to solve the world’s toughest challenges and striving for a world where ‘Health for all Hunger for none’ is no longer a dream, but a real possibility. We’re doing it with energy, curiosity and sheer dedication, always learning from unique perspectives of those around us, expanding our thinking, growing our capabilities and redefining ‘impossible’. There are so many reasons to join us.

If you’re hungry to build a varied and meaningful career in a community of brilliant and diverse minds to make a real difference, there’s only one choice.

Bayer is committed to delivering Health for All by advancing a portfolio of innovative treatments. The company has the passion and determination to develop and commercialize medicines that help improve patients’ lives. To position the company for the future, Bayer has significantly invested in new fields of R&D. One major area of innovation has been Cell Therapy & Gene Therapy (CGT), where we have driven rapid advances via the acquisition of two leading companies in this space, Ask Bio and Blue Rock.

With this investment, Bayer has rapidly built a broad pipeline of assets across a multitude of disease areas. Our assets at the forefront of this pipeline have the potential to transform care for patients with Parkinson’s Disease (PD). Bemdaneprocel (out of Blue Rock) is an experimental cell therapy that has been granted both Fast Track Designation and the Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food & Drug Administration (FDA).

The Phase 1 manuscript from this program was highlighted on the May 22, 2025 cover of Nature, and a Phase 3 registrational study is now ongoing.

Successful commercialization of this asset provides an exciting challenge as we enter this new and important therapeutic area. Cell therapy technologies bring additional complexities with advanced science, sophisticated delivery and distribution models, as well as unique value propositions. Bemdaneprocel promises to be the first successful cell therapy for Parkinson’s disease, with the potential to transformatively impact many lives.

This is a high-impact, high-visibility role that requires an entrepreneurial mindset and a desire to challenge conventional approaches and deliver medical & evidence strategy and leadership for commercial launch. This is a key position on the Global Product Leadership Team. The GME Strategy Lead is responsible for the global medical and evidence strategy for this pioneering cell therapy in Parkinson’s Disease, partnering with Blue Rock colleagues, internal capability clusters, worldwide markets, and key external stakeholders.

• As a key member of the Bemdaneprocel Product Team (PT), the incumbent will work in partnership to co‑create the product strategy to maximize asset value and patient impact;
• As Visionary, Architect, Catalyst, and Coach (VACC), the incumbent provides leadership to define integrated medical and evidence outcomes for optimized asset differentiation and positioning to ensure launch readiness;
• Leads the development of integrated medical affairs and evidence generation strategy, providing medical and evidence input, market insights, critical thinking, and stakeholder perspectives to continuously evolve and calibrate asset strategy and strategic collaborations;
• Leads the Bemdaneprocel PT medical and evidence sub‑teams and works in partnership with relevant colleagues to define and shape the outcomes and missions required to enable successful implementation of the PT integrated medical and evidence plan, including collaboration and input from global evidence leads, medical leads, regional/local medical and evidence colleagues;
• Ensures seamless communication across the Bendaneprocel PT, related customer teams, and all medical and evidence stakeholders involved with the asset, promoting transparency, creativity, and a solution‑oriented mindset;
• Translates business challenges into evidence‑ and insight‑backed solutions, utilizing traditional and innovative methods, inclusive of primary and observational research…